Clinical Trial Update: Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib monotherapy as second-line treatment for patients with RAS-mutant advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: UNKNOWN